Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical...
Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley. We are joined on the...
Black Swan Analysis has been shortlisted for the Micro Business of the Year category, for this year’s Growing Business Awards, in association with Lloyds Bank, supported by Real Business and the CBI....
Although Sickle Cell Disease (SCD) is the most frequent haemoglobinopathy worldwide, it remains a rare blood disorder in most western countries. Globally, an estimated 5% of the world’s population...
In this article, Nic Talbot-Watt, Director of Analysis and Forecasting at Black Swan Analysis, highlights the advantage of having a robust commercial understanding of their healthcare innovation...
Alzheimer’s disease is a form of dementia which is characterised by the loss of brain function, affecting memory, thought patterns and behaviour. In the UK alone there are over 800,000 people who...
Here at Black Swan Analysis, we are very excited to announce the launch of our newly designed Black Swan Analysis website, www.blackswan-analysis.co.uk, that is now live and ready for the world to...
Cystic fibrosis (CF) is a genetically inherited disease shortening the life spans of over 70,000 people worldwide. Over the last decade there has been a significant improvement in diagnosis and...
